Your browser doesn't support javascript.
loading
Risk of Severe Cardiovascular Events From Add-On Tiotropium in Chronic Obstructive Pulmonary Disease.
Liou, Jun-Ting; Lin, Chen Wei; Tsai, Chen-Liang; Wang, Yun-Han; Lai, Jyun-Heng; Hsu, Yu-Juei; Wang, Meng-Ting.
Afiliación
  • Liou JT; Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China.
  • Lin CW; School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China.
  • Tsai CL; Division of Pulmonary and Critical Care, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China.
  • Wang YH; School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China.
  • Lai JH; School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China.
  • Hsu YJ; Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China; Graduate Institutes of Medical Sciences and Biochemistry, National Defense Medical Center, Taipei, Taiwan, Republic of China.
  • Wang MT; School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China. Electronic address: wmt@mail.ndmctsgh.edu.tw.
Mayo Clin Proc ; 93(10): 1462-1473, 2018 10.
Article en En | MEDLINE | ID: mdl-30104044
OBJECTIVE: To examine the risk of cardiovascular disease (CVD) from tiotropium added to inhaled long-acting ß2 agonists (LABAs) and inhaled corticosteroids (ICSs) in a nationwide population with chronic obstructive pulmonary disease (COPD). PATIENTS AND METHODS: This nested case-control study included 65,966 patients with COPD treated with LABAs and ICSs identified from the Taiwan nationwide health care claims database from January 1, 2007, through June 30, 2011. Cases were all patients with a first primary diagnosis of ischemic heart disease, heart failure, stroke, or arrhythmia from inpatient or emergency care settings during follow-up, and each was matched with 4 disease risk score-matched controls from risk sets. The use of tiotropium in the year before the index/event date was measured, stratified by duration since therapy initiation, concomitant COPD medications, and dosage form. Conditional logistic regression models were used to estimate odds ratios of the CVD risk from add-on tiotropium therapy. RESULTS: From the study cohort, with a mean age of 70.3 years (interquartile range, 61.8-79.4 years), 3188 CVD cases (incidence rate, 6.2 [95% CI, 6.0-6.4] cases per 100 person-years) and 12,349 matched controls were identified. The new use of tiotropium was associated with a 1.88-fold (95% CI, 1.44-2.46) increased CVD risk within 30 days of therapy initiation, and the association was sustained up to 60 days after treatment initiation (adjusted odds ratio, 1.71; 95% CI, 1.08-2.70). The risk persisted across all tiotropium regimens, with a case-crossover analysis, and in comparison with new add-on theophylline therapy. CONCLUSION: Tiotropium newly added to LABA/ICS combination therapy was associated with an increased cardiovascular risk in patients with COPD.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Enfermedad Pulmonar Obstructiva Crónica / Bromuro de Tiotropio / Glucocorticoides Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Mayo Clin Proc Año: 2018 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Enfermedad Pulmonar Obstructiva Crónica / Bromuro de Tiotropio / Glucocorticoides Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Mayo Clin Proc Año: 2018 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido